• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Getinge Receives FDA Clearance for Multiple Products

    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry

    TEAM Technologies Acquires ViruDefense

    KORU Medical Systems Names New CEO

    Medtronic Receives FDA Approval for Pipeline Flex Embolization Device with Shield Technology
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Home Is Where the Heart (Valve) Is

    CGM: Digital Health Meets a Very Large Opportunity

    Biomechanical Engineer, Heal Thyself

    Optimizing MIM in Medical Device Manufacturing

    PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    FUTEK Advanced Sensor Technology Inc.

    Trademark Plastics Inc.

    Qosina Corp.

    MW Life Sciences

    Unicep
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    OEMs Increasingly Choosing EMS Providers Closer to Home

    EMS' Engineering Resources Increasingly in Demand

    Fiber Optics Introducing New Cleanliness Requirements for Medical Electronics

    EMS Providers Valued for Product Customization, Medical Certification Expertise

    Three Future Trends and Opportunities in Quality Assurance
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    PTI Engineered Plastics Inc.

    FUTEK Advanced Sensor Technology Inc.

    Medicoil

    Creganna Medical, part of TE Connectivity
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    FDA Offers Update on Efforts to Ensure Breast Implant Safety

    FDA hopes to ensure that women have the most complete information available to make important breast implant decisions.

    Amy Abernethy, M.D., Ph.D., FDA Principal Deputy Commissioner; Jeff Shuren, M.D., J.D., CDRH Director05.06.19
    There has been a growing discussion in recent months around the safety of certain breast implants, with regulatory agencies around the world weighing the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). It’s an issue that has been a priority for us at the U.S. Food and Drug Administration since 2011 when we warned women that the available information at the time indicated that there is a risk for women with breast implants, especially those with textured implants, for developing this disease.
     
    Since that time, we have worked diligently to fill the gaps in knowledge, such as evaluating the body of available evidence regarding the safety and risks of breast implants, including concerns specific to textured implants and the risk of BIA-ALCL. The agency has undertaken several steps to better understand this issue, including an in-depth review of post-approval study data, medical device reports, scientific literature and breast implant-specific registries, and public discussions. But this is not the only issue we’ve been considering with respect to breast implants. The agency has regularly communicated about additional risks associated with breast implants, such as capsular contracture and implant rupture. And we have heard from patients concerned that their implants may be connected to health conditions involving their immune system’s response to these devices, resulting in a variety of symptoms like chronic fatigue, cognitive issues, joint and muscle pain. While the FDA doesn’t have definitive evidence demonstrating breast implants cause these symptoms, the current evidence supports that some women experience systemic symptoms that may resolve when their breast implants are removed, referred to by some patients and health care professionals as breast implant illness. We believe women considering a breast implant should be aware of these risks. As we describe below, we are taking steps to better characterize the condition and its risk factors, and are considering ways to help to ensure women have all of the information they need to make informed decisions about whether to obtain breast implants or to remove existing breast implants in an effort to reverse systemic symptoms.
     
    Most recently, we discussed these important issues in a public advisory committee meeting in March. In the pursuit of our mission to protect the public health, one of the most important things we do as regulators is to listen to the experiences and perspectives of patients, medical and scientific experts and other stakeholders related to medical products. The meeting covered a range of important topics on breast implant safety, including the use of surgical mesh in breast implant surgery, characterization of BIA-ALCL incidence and risk factors, and methods for assessing systemic symptoms. During the two-day meeting, we listened carefully to the insightful comments and personal stories from a broad range of public, scientific, medical and other stakeholders. These insights have been invaluable in growing our understanding of the potential risks associated with breast implants and the need for further efforts to help to ensure appropriate patient protections and improve breast implant safety.
     
    To that end, the information we’ve garnered, from this meeting and other ongoing efforts, makes clear there is an opportunity to do more to protect women considering breast implants. And we are announcing several new steps we have taken and are considering aimed at helping to ensure that women have access to the information they need about breast implants to make informed decisions and to further drive evidence generation that will help the FDA make the most appropriate scientific regulatory decisions moving forward.
     
    First, we will take steps to improve the information available to women and health care professionals about the risks of breast implants that would include addressing the risk of BIA-ALCL, the greater risk of BIA-ALCL with textured implants, and the risk of developing systemic symptoms that would contribute to the patient-provider discussion about breast implants. We are also looking at ways to incorporate product ingredient information into the labeling in a way that is easy for patients to understand. The FDA would work with stakeholders, including patient groups, on the content and format of any labeling changes proposed or recommended by the FDA, which could include a boxed warning and a patient decision checklist, and would work with manufacturers on implementing any changes to the information they provide to health care professionals and patients, including labeling.
     
    We are considering these actions to help to ensure that all women who consider breast implants have the information they need to have thoughtful and balanced discussions with their health care professional about both the benefits and risks of breast implants based on clear information reflecting the most current understanding of these issues.
     
    As we undertake this effort, we recognize that there is a need to help to ensure that information reaches health care professionals and women. We are aware that there are some health care professionals, such as gynecologists, dermatologists, internists and pathologists, who may not be fully aware of these breast implant risks, like BIA-ALCL and systemic symptoms. We are committed to doing what we can to reach them with this important information, including continuing the outreach we started with our Letter to Health Care Providers to educate the medical community about BIA-ALCL and other risks of breast implants. We also plan to work with the pathology community to educate pathologists about testing for this lymphoma specific to breast implants. In addition, we’re committed to continuing to update the public about any new information related to breast implant risks, as well as updating and improving the communication tools we have for women on our website.
     
    We will continue our regular updates about the known global medical device reports for BIA-ALCL, as we have done since 2011. Moving forward, we plan to also regularly communicate information we receive through medical device reports about systemic symptoms experienced by patients with breast implants. We provided information at the two-day advisory committee meeting on medical device reports we’ve received that mention systemic symptoms described by some as breast implant illness, and we plan to continue sharing the numbers of medical device reports on these symptoms.
     
    We are also announcing a change in how breast implant manufacturers file medical device reports with the FDA. We appreciate the value to the public in ensuring this information from medical device reports is readily available to them. In an effort to promote greater public transparency, the FDA has ended all summary reporting of breast implant medical device reports and has notified breast implant manufacturers of this decision. This is part of a larger effort to end the alternative summary reporting program for all medical devices, which we intend to complete in the coming weeks. This program was established in 1997 to more efficiently review adverse events for well-established risks but was not allowed for patient deaths and unusual, unique or uncommon adverse events, which, in the case of breast implants, included BIA-ALCL. Alternative summary reports were not previously available in our public database for medical device reports, Manufacturer and User Facility Device Experience (MAUDE).
     
    Moving forward, breast implant manufacturers will be required to file individual medical device reports that will be publicly available in MAUDE. For past data received through summary reporting, the agency will also be making this data, including alternative summary reports for all devices under the program, publicly available in the coming weeks.
     
    We believe these steps for more transparent medical device reports will contribute to greater public awareness of breast implant adverse events. Increased public awareness of the number of adverse events may contribute to a woman’s own understanding of the risks of breast implants, but, as with any medical device report, it’s important to note that generally the number of reports received cannot be used to determine the frequency with which a particular adverse event occurs. The information in medical device reports is important, but they are only one tool that contributes to our understanding of breast implants. Further, it is important that people understand that the reports are just that – a report by an outside party. The agency has not verified that they are accurate, nor that the issue was in fact caused by the device. For this reason, among others, these reports cannot be used alone to determine an incidence rate, causation or associations as many reports can be duplicative or incomplete.
     
    Partnering with registries, such as the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology, which collects real world data on patients with BIA-ALCL diagnoses, and the new National Breast Implant Registry, which collects real world data on the safety and performance of breast implants, is one way in which we seek to gain greater insight and more comprehensive information about women’s experiences with breast implants.
     
    We expect that both breast implant registries will greatly contribute to helping us evaluate data from providers regarding their patients with breast implants. The data already made available to us from the PROFILE registry provides additional information about patients diagnosed with BIA-ALCL. However, more needs to be done to increase the number of health care professionals contributing to the registries and types of information collected by the registries. The FDA continues to encourage stakeholders that have organized these registries to take steps to expand provider participation; request additional information from providers, such as the patient’s family history of autoimmune disorders and details of past operations; and seek ways to make the data collected more public and transparent, so that patients and researchers can access and analyze the information.
     
    We believe this work with the registries, along with our efforts to address concerns in how the post-approval studies are conducted, will help improve the evidence generated on breast implants and can greatly contribute to our understanding and further assessment of BIA-ALCL, systemic symptoms and other potential long-term risks from breast implants. Better evidence generation leads to more robust and scientifically-sound regulatory decisions.
     
    A few of our international counterparts have started to initiate actions to ban or restrict sales of some textured breast implants, based on concerns about BIA-ALCL. In those markets, there are textured implants that are not marketed in the U.S. and where the use of textured implants is much higher, sometimes as high as 80 percent market share. In 2018, textured breast implants represented less than 10 percent of breast implants sold in the U.S. The type of macro-textured implants targeted by some of our international counterparts represents less than 5 percent of breast implants sold here. At this time, the FDA does not believe that, on the basis of all available data and information, the device meets the banning standard set forth in the Federal Food, Drug and Cosmetic Act.
     
    The FDA believes regulatory action must be based on scientific data. While the majority of women who develop BIA-ALCL have had textured implants, there are known cases in women with smooth-surface breast implants and many reports do not include the surface texture of the implant at the time of diagnosis. We are focused on strengthening the evidence generated to help inform future regulatory actions and to assure that women and providers are adequately informed of the risk of BIA-ALCL, including that the risk is higher with the use of textured implants, albeit still low. We are still investigating the cause of the association and we will continue to monitor, assess and report our findings as we continue to strengthen our evidence collected so that women and providers can be better informed about BIA-ALCL as they consider breast implants.
     
    Taken together, we believe these efforts to improve communication and focus on evidence generation will contribute significantly to improving the safety of breast implants and want to share that many of these efforts are already underway. We are committed to making a difference for women’s health and will continue working towards ensuring we understand the benefits and risks of these devices, and that women have the most complete information available to make important breast implant decisions.
    Related Searches
    • change
    • it
    • user
    • ban
    Related Knowledge Center
    • Surgical

    Related Breaking News

    • Surgical
      Katena Acquires Ophthalmic Surgical Instrument Maker ASICO

      Katena Acquires Ophthalmic Surgical Instrument Maker ASICO

      Katena obtains high-quality ophthalmic surgical instruments.
      Sam Brusco, Associate Editor 04.14.21

    • Cardiovascular | Surgical
      Abbott

      Abbott's Next-Gen TriClip Earns EU Nod

      New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve.
      Sam Brusco, Associate Editor 04.08.21

    • Surgical
      Bausch + Lomb

      Bausch + Lomb's ClearVisc Dispersive Ophthalmic Viscosurgical Device Approved

      Offers corneal protection and visibility during ophthalmic surgery.
      Sam Brusco, Associate Editor 04.07.21


    • Surgical
      Royal Philips’ SmartCT Application Software Receives FDA 510(k) Clearance

      Royal Philips’ SmartCT Application Software Receives FDA 510(k) Clearance

      Helps enhance clinical confidence, smooths workflows, and increases productivity.
      Charles Sternberg, Assistant Editor 04.06.21

    • Surgical
      Ethicon Launches Echelon+ Stapler

      Ethicon Launches Echelon+ Stapler

      Increases staple line security and reduces complications in surgery.
      Charles Sternberg, Assistant Editor 04.01.21

    • Surgical
      Boston Scientific to Pay $189M to Settle Charges Over Surgical Mesh

      Boston Scientific to Pay $189M to Settle Charges Over Surgical Mesh

      The company misled consumers about its surgical mesh devices' safety and effectiveness.
      Sam Brusco, Associate Editor 03.25.21


    • Surgical
      Olympus Files Patent Suit Against Cantel/Medivators

      Olympus Files Patent Suit Against Cantel/Medivators

      Alleges AmplifEye Endoscopic Device infringes on two Olympus patents for its ENDOCUFF single-use devices.
      Sam Brusco, Associate Editor 03.23.21

    • Cardiovascular | Surgical
      CSI Buys Peripheral Support Catheters from WavePoint Medical

      CSI Buys Peripheral Support Catheters from WavePoint Medical

      Agreement also includes development of portfolio of chronic total occlusion products.
      Sam Brusco, Associate Editor 03.22.21

    • Surgical
      FDA OKs Asensus

      FDA OKs Asensus' Senhance for General Surgery

      Indication expansion allows Senhance's use in high-value, complex reconstructive surgeries.
      Sam Brusco, Associate Editor 03.03.21


    • Surgical
      Boston Scientific to Buy Lumenis

      Boston Scientific to Buy Lumenis' Surgical Biz for $1B

      Gains laser systems, fibers, and accessories for urology and otolaryngology procedures.
      Sam Brusco, Associate Editor 03.03.21

    • Surgical
      Memic Receives FDA Marketing Authorization for Hominis

      Memic Receives FDA Marketing Authorization for Hominis

      Its robot-assisted surgical platform is now available for use in transvaginal gynecologic procedures including benign hysterectomy.
      Charles Sternberg, Assistant Editor 03.02.21

    • Surgical
      Olympus to Purchase Israeli Firm Medi-Tate to Grow Urology Biz

      Olympus to Purchase Israeli Firm Medi-Tate to Grow Urology Biz

      Medi-Tate's iTind nitinol implant supports lower urinary tract symptom relief due to benign prostatic hyperplasia.
      Sam Brusco, Associate Editor 03.02.21


    • Surgical
      TransEnterix Changes Name to Asensus Surgical

      TransEnterix Changes Name to Asensus Surgical

      The rebranded firm also introduced a new surgical category—performance-guided surgery.
      Sam Brusco, Associate Editor 02.24.21

    • Surgical
      FDA Green Lights EPI

      FDA Green Lights EPI's EndoClot Hemostat to Manage GI Bleeding

      Rapidly and reliably controls bleeding during GI procedures.
      Sam Brusco, Associate Editor 02.23.21

    • Surgical
      Apollo Endosurgery to Welcome New Leader

      Apollo Endosurgery to Welcome New Leader

      Charles (Chas) McKhann will become CEO of the company on March 1.
      Sam Brusco, Associate Editor 02.08.21


    Trending
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • J&J’s Veritas Vision System Receives FDA Clearance And CE Mark
    • Top 10 Trends In The Medical Device And Equipment Industry
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • Johnson & Johnson Vision Unveils Acuvue Abiliti
    Breaking News
    • Getinge Heart Lung Machine Becomes Available for European Hospitals
    • Getinge Receives FDA Clearance for Multiple Products
    • Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    • TEAM Technologies Acquires ViruDefense
    • KORU Medical Systems Names New CEO
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Transporting Treatment: An Examination of Tubing Technologies
    • Face to (Virtual) Face: Telemedicine Now and Post-Pandemic
    • Outward Appearance: Reviewing Surface Treatment Options
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    Axalta Wins Three 2021 Edison Awards
    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    PPG Maintains EcoVadis Gold Rating
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Heart Lung Machine Becomes Available for European Hospitals
    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lonza to Build Small Molecule Manufacturing Complex in Visp
    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    KKW Launches Fragrance Bundle with Jeff Leatham
    Love Beauty and Planet Announces Sustainability Initiatives
    Coty Shares Long-Term Strategy
    Happi

    Latest Breaking News From Happi

    Spectrum Brands Acquires Rejuvenate Household Cleaning Products
    Pravana Joins PETA’s Beauty without Bunnies Program
    A New Chief Digital Officer at L'Oréal
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Ravenwood introduces water resistant linerless paper
    Ashland commits to forest restoration
    Epson upgrades SurePress demo facility
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Fibertex Nonwovens Announces European Investments
    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login